BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31579206)

  • 1. Metachronous Second Primary Malignancies in Known Breast Cancer Patients on 18F-Fluoro-2-Deoxyglucose Positron Emission Tomography-Computerized Tomography in a Tertiary Care Center.
    Manthri RG; Jeepalem SM; Krishna Mohan VS; Bhargavi D; Hulikal N; Kalawat T
    Indian J Nucl Med; 2019; 34(4):284-289. PubMed ID: 31579206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
    Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer.
    Ueda S; Tsuda H; Asakawa H; Omata J; Fukatsu K; Kondo N; Kondo T; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
    BMC Cancer; 2008 Jun; 8():165. PubMed ID: 18541009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
    Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
    Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
    Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
    J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of 18F-FDG PET-CT in the detection of unknown primary malignancy: a retrospective study.
    Yaylali O; Kiraç FS; Yüksel D
    Turk J Med Sci; 2016 Feb; 46(2):474-82. PubMed ID: 27511514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons between glucose analogue 2-deoxy-2-((18)F)fluoro-D-glucose and (18)F-sodium fluoride positron emission tomography/computed tomography in breast cancer patients with bone lesions.
    Capitanio S; Bongioanni F; Piccardo A; Campus C; Gonella R; Tixi L; Naseri M; Pennone M; Altrinetti V; Buschiazzo A; Bossert I; Fiz F; Bruno A; DeCensi A; Sambuceti G; Morbelli S
    World J Radiol; 2016 Feb; 8(2):200-9. PubMed ID: 26981229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is 18F-fluorodeoxyglucose positron emission tomography/computed tomography useful to discriminate metachronous lung cancer from metastasis in patients with oncological history?
    Taralli S; Scolozzi V; Triumbari EK; Carleo F; Di Martino M; De Massimi AR; Ricciardi S; Cardillo G; Calcagni ML
    Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):291-298. PubMed ID: 30654605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response evaluation of cervical lymph nodes after chemoradiation in patients with head and neck cancer - does additional [18F]FDG-PET-CT help?
    Dejaco D; Uprimny C; Widmann G; Riedl D; Moser P; Arnold C; Steinbichler TB; Kofler B; Schartinger VH; Virgolini I; Riechelmann H
    Cancer Imaging; 2020 Sep; 20(1):69. PubMed ID: 32993805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
    Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
    Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of 18F-FDG-PET/CT in early detection of second primary malignancy in cancer patients.
    Xu H; Zhang M; Zhai G; Li B
    J Cancer Res Clin Oncol; 2010 Aug; 136(8):1125-34. PubMed ID: 20091320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
    Kumar R; Hawkins RA; Yeh BM; Wang ZJ
    Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of qualitative assessment in detecting synchronous and metachronous malignancies in adult cancer patients by 18F-FDG PET/CT.
    Lau JHY; Ng KK; Wong WC; Ng KS; Chu KS; Au-Yong TK; Kung BT
    Nucl Med Commun; 2024 May; ():. PubMed ID: 38726624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer.
    Vadi SK; Mittal BR; Sood A; Singh G; Bal A; Parihar AS; Bhattacharya A; Basher RK; Kapoor R
    Nucl Med Commun; 2019 Jan; 40(1):63-72. PubMed ID: 30312217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.